Yamada Jiko, Tomiyama Hirofumi, Matsumoto Chisa, Yoshida Masanobu, Shiina Kazuki, Yamashina Akira
Second Department of Internal Medicine, Tokyo Medical University, 6-7-1 Nishi-Shinjuku, Tokyo 160-0023, Japan.
J Cardiol. 2008 Apr;51(2):114-20. doi: 10.1016/j.jjcc.2008.01.005.
The present study was conducted to clarify whether azelnidipine might have beneficial effects on autonomic functions, and whether such beneficial effects might affect the vascular functions (i.e., arterial stiffness and endothelial function).
This study with a cross-over design was conducted in 21 hypertensive patients (65 +/- 9 years old) being treated with calcium channel blockers (CCBs) other than azelnidipine or benidipine (i.e., during the study period, the CCB was switched to either azelnidipine 16 mg/day or benidipine 4 mg/day, administered alternately for 8 weeks each). Blood examinations were conducted and the heart rate variability, baro-receptor sensitivity (BRS), brachial-ankle pulse wave velocity (baPWV) and flow-mediated vasodilatation (FMD) in the brachial artery were measured after treatment with each of the two drugs. While the blood pressure levels decreased to a similar degree after both treatments, the BRS (8.8 +/- 5.5 ms/mmHg vs. 6.4 +/- 2.9 ms/mmHg, p < 0.01) and high-frequency power component (HF: 139 +/- 152 ms2/Hz vs. 88 +/- 97 ms2/Hz) were higher after treatment with azelnidipine than after treatment with benidipine (p < 0.05). However, the baPWV, FMD and plasma levels of malonyldialdehyde low-density lipoprotein cholesterol and nitric oxides were similar after treatment with both drugs.
Azelnidipine has greater beneficial effects on the autonomic functions than benidipine although the degree of reduction of blood pressure induced by the two drugs was similar. However, this greater beneficial effect of azelnidipine on the autonomic functions did not produce any distinguishable differences in effects of azelnidipine and benidipine on the arterial stiffness and endothelial functions.
本研究旨在阐明阿折地平是否对自主神经功能具有有益作用,以及这种有益作用是否会影响血管功能(即动脉僵硬度和内皮功能)。
本研究采用交叉设计,对21例正在接受除阿折地平或贝尼地平以外的钙通道阻滞剂(CCB)治疗的高血压患者(65±9岁)进行研究(即在研究期间,将CCB换为阿折地平16mg/天或贝尼地平4mg/天,每种药物交替给药8周)。进行血液检查,并在两种药物治疗后测量心率变异性、压力感受器敏感性(BRS)、臂踝脉搏波速度(baPWV)和肱动脉血流介导的血管舒张(FMD)。虽然两种治疗后血压水平均下降至相似程度,但阿折地平治疗后的BRS(8.8±5.5ms/mmHg对6.4±2.9ms/mmHg,p<0.01)和高频功率分量(HF:139±152ms2/Hz对88±97ms2/Hz)高于贝尼地平治疗后(p<0.05)。然而,两种药物治疗后baPWV、FMD以及丙二醛、低密度脂蛋白胆固醇和一氧化氮的血浆水平相似。
尽管两种药物引起的血压降低程度相似,但阿折地平对自主神经功能的有益作用大于贝尼地平。然而,阿折地平在自主神经功能方面的这种更大有益作用并未在阿折地平和贝尼地平对动脉僵硬度和内皮功能的影响上产生任何明显差异。